0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Immune Checkpoint Proteins > TIGIT > Human TIGIT Protein, Mouse IgG2a Fc Tag, low endotoxin

Human TIGIT Protein, Mouse IgG2a Fc Tag, low endotoxin

  • Synonym
    TIGIT,VSIG9,VSTM3
  • Source
    Human TIGIT, Mouse IgG2a Fc Tag, low endotoxin (TIT-H5253) is expressed from human 293 cells (HEK293). It contains AA Met 22 - Pro 141 (Accession # AAI01290).
    Predicted N-terminus: Met 22
  • Molecular Characterization
    Online(Met 22 - Pro 141) AAI01290

    This protein carries a mouse IgG2a Fc tag at the C-terminus.

    The protein has a calculated MW of 40.1 kDa. The protein migrates as 42-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 0.1 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    No activity loss was observed after storage at:

    1. 4-8°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human TIGIT, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. TIT-H5253) SDS-PAGE gel

Human TIGIT, Mouse IgG2a Fc Tag, low endotoxin on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Human TIGIT, Mouse IgG2a Fc Tag, low endotoxinHuman TIGIT, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. TIT-H5253) ELISA bioactivity

Immobilized Human CD155, Fc Tag (Cat. No. CD5-H5251) at 5 μg/mL (100 μL/well) can bind Human TIGIT, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. TIT-H5253) with a linear range of 0.5-8 ng/mL (QC tested).

Human TIGIT, Mouse IgG2a Fc Tag, low endotoxinHuman TIGIT, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. TIT-H5253) ELISA bioactivity

Serial dilutions of TIGIT antibody antibody (1:2 serial dilutions, from 20 μg/mL to 0.0097 μg/mL) were added into Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253): Biotinylated Human Nectin-2, Fc,Avitag (Cat. No. CD2-H82F8) binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points before curve fitting.

Bioactivity-FACS
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that Human TIGIT, Mouse IgG2a Fc tag, low endotoxin (Cat. No. TIT-H5253) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.03 μg/mL (Routinely tested).

  • Background
    TIGIT (also called T cell immunoreceptor with Ig and ITIM domains) is one newly discovered immune receptor on some percentage of T cells and Natural Killer Cells(NK). It is also identified as WUCAM and Vstm3. TIGIT could bind to CD155(PVR) on dendritic cells(DCs), macrophages, etc. with high affinity, and also to CD112(PVRL2) with lower affinity. TIGIT expressing CD8+ T cells has been shown to be expanded and associated with clinical markers of HIV disease progression in a diverse group of HIV infected individuals. TIGIT and PD-1 has been shown to be over expressed on tumor antigen-sepcific (TA-specific) CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TILs) from individuals with melanoma. Blockade of TIGIT and PD-1 led to increased cell proliferation, cytokine production, and degranulation of TA-specific CD8+ T cells and TIL CD8+ T cells.
  • References
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $350.00

Price(USD) : $2100.00

Promotion & Exhibitions

  • PEGS Boston 2019
  • PepTalk 2019

Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:4 Details
  • Latest Research Phase:Phase ?

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop